Emergent Biosolutions Inc. (NYSE:EBS) Director Sells $67,850.60 in Stock

Key Points

• Director Donald W. Degolyer of Emergent Biosolutions Inc. sold 7,844 shares at an average price of $8.65, totaling $67,850.60, resulting in a 5.39% decrease in his stock position.
• The company reported a quarterly EPS of $0.16, exceeding consensus estimates, but its revenue of $140.90 million fell short of expectations of $148.55 million.
• Wall Street Zen downgraded Emergent Biosolutions from a "buy" to a "hold" rating, reflecting shifting analyst sentiment towards the stock.

Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) Director Donald W. Degolyer sold 7,844 shares of the company's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $8.65, for a total transaction of $67,850.60. Following the completion of the sale, the director owned 137,659 shares in the company, valued at $1,190,750.35. This represents a 5.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Emergent Biosolutions Price Performance

Shares of NYSE EBS traded down $0.14 during mid-day trading on Wednesday, reaching $8.77. 1,459,186 shares of the company were exchanged, compared to its average volume of 1,261,451. Emergent Biosolutions Inc. has a 52 week low of $4.02 and a 52 week high of $13.28. The company has a quick ratio of 3.00, a current ratio of 5.66 and a debt-to-equity ratio of 1.25. The stock has a market capitalization of $467.88 million, a PE ratio of 3.58 and a beta of 1.97. The company's 50 day moving average price is $6.81 and its 200 day moving average price is $6.61.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.16 EPS for the quarter, beating the consensus estimate of ($0.26) by $0.42. Emergent Biosolutions had a net margin of 16.38% and a return on equity of 24.63%. The firm had revenue of $140.90 million during the quarter, compared to the consensus estimate of $148.55 million. Sell-side analysts forecast that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Wall Street Zen lowered shares of Emergent Biosolutions from a "buy" rating to a "hold" rating in a research note on Saturday.

Institutional Investors Weigh In On Emergent Biosolutions

Institutional investors have recently made changes to their positions in the company. New York State Common Retirement Fund boosted its position in shares of Emergent Biosolutions by 4.9% during the second quarter. New York State Common Retirement Fund now owns 393,575 shares of the biopharmaceutical company's stock worth $2,511,000 after acquiring an additional 18,541 shares during the last quarter. Ameritas Investment Partners Inc. bought a new position in shares of Emergent Biosolutions during the second quarter valued at approximately $35,000. Rhumbline Advisers boosted its holdings in shares of Emergent Biosolutions by 862.4% in the 2nd quarter. Rhumbline Advisers now owns 84,025 shares of the biopharmaceutical company's stock valued at $536,000 after buying an additional 75,294 shares in the last quarter. Legal & General Group Plc purchased a new stake in Emergent Biosolutions in the second quarter valued at about $31,000. Finally, Intech Investment Management LLC purchased a new position in shares of Emergent Biosolutions in the second quarter worth about $183,000. Hedge funds and other institutional investors own 78.40% of the company's stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.